Original Article |
Corresponding author: Gaurang Dubal ( dr.gaurangdubal@gmail.com ) © 2022 Mukeshkumar Vachhani, Jaydeep Lalpara, Sanjay Hadiyal, Gaurang Dubal.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Vachhani M, Lalpara J, Hadiyal S, Dubal G (2022) Microwave-assisted synthesis of bioactive tetrahydropyrimidine derivatives as antidiabetic agents. Folia Medica 64(3): 478-487. https://doi.org/10.3897/folmed.64.e62476
|
Abstract
Introduction: In drug discovery, pyrimidine analogues show good biological response and many drug moieties have pyrimidine core.
Aim: On the basis of prior review, we synthesized a series of N-(substituted phenyl)-1,3,6-trimethyl-4-(4-((5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl)methoxy)phenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide parade a 1,3,4-oxadiazole core which were evaluated for in vitro antidiabetic screening.
Materials and methods: The tetrahydropyrimidine derivatives have been synthesized by microwave irradiation method. It was carried out by Biginelli condensation of 1,3,4-oxadiazole based aldehyde, substituted acetoacetanilide and N,N’-dimethyl urea. All synthesized compounds were evaluated for antidiabetic screening.
Results: By the results derived from antidiabetic activity, compounds 4a, 4e, 4g, and 4i show good inhibition compared to others because of electron withdrawing and hydroxyl groups. All results are compared with standard drug acarbose.
Conclusions: In conclusion, a series of 1,3,4-oxadizole bearing tetrahydropyrimidine has been synthesized and evaluated for in vitro antidiabetic screening. The derivatives 4a, 4e, 4g, and 4i exhibited promising antidiabetic activity.
1, 3, 4-oxadiazole, antidiabetic activity, microwave irradiation, tetrahydropyrimidine
Heterocyclic moieties have been broadly employed in the synthesis of pharmacologically active entities.[
We developed a series of 1,3,4-oxadiazole bearing tetrahydropyrimidine derivatives. Both the moieties pyrimidine and 1,3,4-oxadiazole parade wide range of biological response (Fig.
All chemicals, solvents, and media were purchased from Sigma Aldrich, combi-block, enamine, Himedia, SRL. All purchased chemicals were used without further purification, reactions were continuously monitored by thin layer chromatography (TLC) on silica gel-(G60 F254, Merck) of 0.5 mm thickness, visualizing with ultraviolet light (254 and 365 nm), or with iodine vapour or aq KMnO4. Melting points were determined using a Buchi B-540 capillary apparatus. NMR spectra were recorded on a Bruker Advance 400 MHz spectrometer (400 MHz for 1H NMR and 101 MHz for 13C NMR) respectively in solvents like CDCl3, DMSO and chemical shifts were referenced to the solvent residual signals with respect to tetramethylsilane. Standard abbreviations are used to represent signals multiplicities for 1H NMR spectrum s - singlet, d - doublet, t - triplet, q - quartet, m - multiplate. The reaction temperature was monitored by ruby thermometer. Mass spectra were recorded on a Shimadzu GC-MS-QP-2010 mass spectrometer in EI (70eV) model using direct inlet probe technique and m/z were reported in atomic units per elementary charge.
To mixture of 4-nitrobenzohydrazide (10 mmol) and chloroacetic acid (10 mmol) in POCl3 (5 ml) solvent and reflux at 80-90°C for 4-5 hours. Reaction progress was continuously monitored by TLC using hexane: ethyl acetate (7:3) as mobile phase. After completion of reaction, product precipitated in crushed ice water. The reaction mass was filtered using Whatman filter paper and dried under vacuum dryer. White amorphous solid was obtained (Int-1).
To mixture of 2-(chloromethyl)-5-(4-nitrophenyl)-1,3,4-oxadiazole (Int-1) (1 mmol) and 4-hydroxybenzaldehyde (1 mmol) in acetonitrile (5 ml) solvent and heated at reflux condition for 5 hours. K2CO3 (10 mol%) was added as a catalyst in reaction mixture. Reaction progress was continuously monitored by TLC using hexane:ethyl acetate (7:3) as mobile phase. After completion of reaction, the product precipitated in crushed ice water. The reaction mass was filtered using Whatman filter paper and dried under vacuum dryer. Brown solid was obtained (1).
To mixture of 4-((5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl) methoxy) benzaldehyde (1) (1 mmol), N,N’-Dimethylurea (1 mmol) (3) and substituted acetoacetanilide (1 mmol) (2a-j) in ethanol solvent for 20-24 hours at reflux condition. Reaction progress was continuously monitored by TLC using hexane:ethyl acetate (7:3) as mobile phase. After completion of reaction, product fallout in crushed ice water. The reaction mass was filtered using Whatman filter paper and dried under vacuum to get crude material which was purified by column chromatography using 30% ethyl acetate/n-hexane as a mobile phase to get pure compounds (4a-j).
To mixture of 4-((5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl) methoxy) benzaldehyde (1) (1 mmol), N,N’-Dimethylurea (1 mmol) (3) and substituted acetoacetanilide (1 mmol) (2a-j) in ethanol solvent under microwave irradiation condition for 22-24 min. Reaction progress was continuously monitored by TLC using hexane:ethyl acetate (7:3) as mobile phase. After completion of reaction, product fallout in crushed ice water. The reaction mass was filtered using Whatman filter paper and dried under vacuum to get crude material which was purified by column chromatography using 30% ethyl acetate/n-hexane as a mobile phase to get pure compounds (4a-j).
All compounds (4a-j) synthesized by the above mentioned method and structure of compounds were confirmed by various spectroscopic techniques such as 1H NMR, 13C NMR, and mass spectrometry.
Yield: 92%, colour: light yellowish powder, m.p. (°C): 250–254. IR (KBr, νmax, cm-1) : (-N-H amidic), 3045 (=C-H aromatic), 2912 & 2894 (-C-H aliphatic), 1697 (-CONH amidic ketone), 1642 & 1592 (C=C aromatic), 1542 (-NO2 asymmetric), 1341 (-NO2 symmetric), 1307 (-C-O-C asymmetric), 1175 (-C-N), 1042 (-C-O-C symmetric), 874 (p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.11 (s, 1H, -NH), 8.46-8.53 (m, 1H, aromatic), 8.37-8.48 (m, 1H, Phenyl), 8.15-8.26 (m, 4H, aromatic), 7.94-8.06 (m, 1H, aromatic), 7.75 (d, J=6.2 Hz, 2H, aromatic), 7.15-7.23 (m, 2H, aromatic), 6.61 (d, J=5.9 Hz, 1H, aromatic), 4.79 (d, J=3.5, 2H, -CH2), 4.17 (s, 1H, Chiral -CH), 3.40 (s, 3H, -CH3) 3.07 (s, 6H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 166.81, 163.99, 161.32, 159.38, 155.68, 149.38, 148.62, 139.14, 137.88, 135.55, 129.12, 129.01, 128.80, 127.33, 126.37, 123.72, 115.19, 112.33, 70.23, 66.05, 28.34, 30.21, 13.99. Mass m/z: 599. Elemental Analysis: C29H25N7O7; Calculated: C, 58.10; H, 4.20; N, 16.35; Found: C, 58.06; H, 4.15; N, 16.32.
Yield: 86%, colour: dark brown colour powder, m.p. (°C): 250–254. IR (KBr, νmax, cm-1): 3365 (N-H amidic), 3081 (=C-H aromatic), 2947 & 2900 (-C-H aliphatic), 1685 (-CONH amidic ketone), 1641 & 1598 (C=C aromatic), 1524 (-NO2 asymmetric), 1352 (NO2 symmetric), 1305 (=C-O-C asymmetric), 1175 (C-N), 1072 (=C-O-C symmetric), 833 (p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.10 (s, 1H, -NH), 8.40-8.52 (m, 1H, aromatic), 8.34-8.41 (m, 4H, aromatic), 8.08-8.23 (m, 1H, aromatic), 7.89-7.93 (m, 1H, aromatic), 7.68 (d, J=6.1 Hz, 2H, aromatic), 7.13 (m, 2H, aromatic), 6.54 (d, J=5.5 Hz, 1H, aromatic), 4.77 (d, J=3.5, 2H, -CH2), 4.10 (s, 1H, Chiral -CH), 3.01 (s, 3H, -CH3), 3.15 (s, 3H, -CH3), 2.98 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 166.81, 163.99, 161.32, 159.38, 155.68, 149.38, 148.62, 139.14, 137.88, 135.55, 129.12, 129.01, 128.80, 127.33, 126.37, 123.72, 115.19, 112.33, 70.23, 66.05, 28.34, 30.21, 13.99. Mass m/z: 620. Elemental Analysis: C29H25BrN6O6: Calculated: C, 54.99; H, 3.98; N, 13.27; Found: C, 54.94; H, 3.92; N, 13.23.
Yield: 86%, colour: dark brown color powder, m.p. (°C): 250–254. IR (KBr, νmax, cm-1): 3365 (-N-H amidic), 3081 (=C-H aromatic), 2947 & 2900 (-C-H aliphatic), 1685 (-CONH amidic ketone), 1641 & 1598 (C=C aromatic), 1524 (-NO2 asymmetric), 1352 (NO2 symmetric), 1305 (=C-O-C asymmetric), 1175 (C-N), 1072 (=C-O-C symmetric), 833 (p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.02 (s, 1H, -NH), 8.35-8.46 (m, 1H, aromatic), 8.23-8.39 (m, 4H, aromatic), 7.80-7.84 (m, 2H, aromatic), 7.59 (d, J=6.1 Hz, 2H, aromatic), 7.05-7.12 (m, 2H, aromatic), 6.48 (d, J=5.5 Hz, 1H, aromatic), 4.64 (d, J=3.5, 2H, -CH2), 4.02 (s, 1H, Chiral -CH), 3.15 (s, 3H, -CH3), 3.05 (s, 3H, -CH3), 2.98 (s, 3H, -CH3) 2.19 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.24, 163.38, 160.17, 158.42, 155.68, 148.48, 147.99, 139.14, 137.88, 135.55, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 20.14, 13.99. Mass m/z: 568. Elemental Analysis: C30H28N6O6: Calculated: C, 63.37; H, 4.96; N, 14.78; Found: C, 63.34; H, 4.92; N, 14.71.
Yield: 89%, colour: off white powder, m.p. (°C): 212–214. IR (KBr, νmax, cm-1): 3379 (N-H cyclic), 3245 (-N-H amidic), 3098 (=C-H aromatic), 2957 & 2893 (-C-H aliphatic), 1668 (-CONH amidic), 1613 & 1589 (C=C aromatic), 1512 (NO2 asymmetric), 1325 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 830 (p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.04 (s, 1H, -NH), 8.44 (m, 1H, aromatic), 8.31-8.43 (m, 1H, aromatic), 8.10-8.23 (m, 4H, aromatic), 7.89-7.99 (m, 1H, aromatic), 7.72 (d, J=6.2 Hz, 2H, aromatic), 7.11-7.25 (m, 2H, aromatic), 6.55 (d, J=5.4 Hz, 1H, aromatic), 4.76 (d, J=2.98, 2H, -CH2), 4.13 (s, 1H, Chiral -CH), 3.20 (s, 3H, -CH3), 3.15 (s, 3H, -CH3), 2.98 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 166.04, 16.31, 160.17, 158.45, 155.53, 148.72, 147.89, 139.27, 137.76, 135.55, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 13.99. Mass m/z: 576. Elemental Analysis: C27H21ClN6O6; Calculated: C, 59.14; H, 4.28; N, 14.27; Found: C, 59.11; H, 4.25; N, 14.21.
Yield: 87%, colour: violet crystal, m.p. (C): 179–182. IR (KBr, νmax, cm-1): 3370 (N-H cyclic), (-N-H amidic), 3090 (=C-H aromatic), 2962 & 2900 (-C-H aliphatic), 1686 (-CONH amidic), 1639 & 1585 (C=C aromatic), 1531 (-NO2 asymmetric), 1342 (-NO2 symmetric), 1308 (-C-O-C asymmetric), 1142 (C-N), 1068 (-C-O-C symmetric), 856 (C-H p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.02 (s, 1H, -NH), 8.41 (m, 1H, aromatic), 8.32 (m, 1H, aromatic), 8.07-8.19 (m, 4H, aromatic), 7.90-8.02 (m, 1H, aromatic), 7.69 (d, J=5.9 Hz, 2H, aromatic), 7.11-7.24 (m, 2H, aromatic), 6.57 (d, J=5.7 Hz, 1H, Phenyl), 4.71 (d, J=3.3, 2H, -CH2), 4.10 (s, 1H, Chiral -CH), 3.20 (s, 3H, -CH3), 3.01 (s, 3H, -CH3), 2.94 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.12, 163.27, 160.20, 158.76, 155.11, 148.49, 147.73, 139.42, 137.56, 135.48, 129.81, 128.43, 128.37, 127.67, 126.77, 123.89, 115.28, 112.11, 70.45, 66.33, 28.37, 30.12, 13.86. Mass m/z: 572. Elemental Analysis: C29H25FN6O6; Calculated: C, 60.84; H, 4.40; N, 14.68; Found: C, 60.79; H, 4.37; N, 14.65.
Yield: 89%, colour: off white powder, m.p. (°C): 212–214. IR (KBr, νmax, cm-1): 3379 (N-H cyclic), 3245 (-N-H amidic), 3098 (=C-H aromatic), 2957 & 2893 (-C-H aliphatic), 1668 (-CONH amidic), 1613 & 1589 (C=C aromatic), 1512 (NO2 asymmetric), 1325 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 695 (o-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.03 (s, 1H, -NH), 8.54-8.62 (m, 1H, aromatic), 8.35-8.48 (m, 1H, aromatic), 8.05-8.22 (m, 4H, aromatic), 7.85-7.92 (m, 1H, aromatic), 7.78 (d, J=6.3 Hz, 2H, aromatic), 7.11-7.23 (m, 2H, aromatic), 6.61 (d, J=5.4 Hz, 1H, aromatic), 4.78 (d, J=3.0, 2H, -CH2), 4.10 (s, 1H, Chiral -CH), 3.17 (s, 3H, -CH3), 3.12 (s, 3H, -CH3), 2.94 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 166.04, 16.31, 160.17, 158.45, 155.53, 148.72, 147.89, 139.27, 137.76, 135.55, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 13.99. Mass m/z: 576. Elemental Analysis: C27H21ClN6O6; Calculated: C, 59.14; H, 4.28; N, 14.27; Found: C, 59.10 s; H, 4.25; N, 14.21.
Yield: 83%, colour: brown colour powder, m.p. (°C):235–238. IR (KBr, νmax, cm-1): 3368 (-OH, aromatic), 3256 (N-H amidic), 3078 (=C-H aromatic), 2962 & 2900 (-C-H aliphatic), 1685 (-CONH amidic), 1641 & 1598 (C=C aromatic), 1524 (NO2 asymmetric), 1352 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 842 (p-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.00 (s, 1H, -NH), 8.36-8.48 (m, 1H, aromatic), 8.31-8.42 (m, 1H, aromatic), 8.09-8.22 (m, 4H, aromatic), 7.85-7.92 (m, 1H, aromatic), 7.64 (d, J=5.9 Hz, 2H, aromatic), 7.11-7.26 (m, 2H, aromatic), 6.53 (d, J=5.8 Hz, 1H, aromatic), 5.02 (s, 1H, -OH) 4.76 (d, J=3.1, 2H, -CH2), 4.15 (s, 1H, Chiral -CH), 3.12 (s, 3H, -CH3), 2.15 (s, 3H, -CH3). 2.94 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.45, 163.99, 160.74, 158.26, 155.49, 148.72, 147.89, 139.27, 137.76, 135.55, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 13.99. Mass m/z: 570. Elemental Analysis: C29H26N6O7; Calculated: C, 61.05; H, 4.59; N, 14.73; Found: C, 61.01; H, 4.53; N, 14.70.
Yield: 89%, colour: off white powder, m.p. (°C): 212–214. IR (KBr, νmax, cm-1): 3379 (N-H cyclic), 3245 (-N-H amidic), 3098 (=C-H aromatic), 2957 & 2893 (-C-H aliphatic), 1668 (-CONH amidic), 1613 & 1589 (C=C aromatic), 1512 (NO2 asymmetric), 1325 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 695 (o-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.03 (s, 1H, -NH), 8.54-8.62 (m, 1H, aromatic), 8.35-8.48 (m, 1H, aromatic), 8.05-8.22 (m, 4H, aromatic), 7.85-7.92 (m, 1H, aromatic), 7.78 (d, J=6.3 Hz, 2H, aromatic), 7.11-7.23 (m, 2H, aromatic), 6.61 (d, J=5.4 Hz, 1H, aromatic), 4.78 (d, J=3.0, 2H, -CH2), 4.10 (s, 1H, Chiral -CH), 3.17 (s, 3H, -CH3), 3.12 (s, 3H, -CH3), 2.94 (s, 3H, -CH3), 2.19 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.24, 163.38, 160.17, 158.42, 155.68, 148.48, 147.99, 139.14, 137.88, 135.55, 130.54, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 20.14, 13.99. Mass m/z: 568. Elemental Analysis: C30H28N6O6: Calculated: C, 63.37; H, 4.96; N, 14.78; Found: C, 63.34; H, 4.92; N, 14.71.
Yield: 82%, colour: dark brown colour powder, m.p. (°C): 195–198. IR (KBr, νmax, cm-1): 3261 (-N-H amidic), 3075 (=C-H aromatic), 2962 & 2900 (-C-H aliphatic), 1685 (-CONH amidic), 1641 & 1598 (-C=C aromatic), 1524 (-NO2 asymmetric), 1352 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 675 & 710 (m-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.04 (s, 1H, -NH), 8.40-8.51 (m, 1H, Phenyl), 8.32-8.48 (m, 1H, aromatic), 8.05-8.21 (m, 4H, aromatic), 7.88-7.98 (m, 1H, aromatic), 7.71 (d, J=6.0 Hz, 2H, aromatic), 7.00-7.13 (m, 2H, aromatic), 6.54 (d, J=5.2 Hz, 1H, aromatic), 4.70 (d, J=3.1, 2H, -CH2), 4.06 (s, 1H, Chiral -CH), 3.12 (s, 3H, -CH3) 2.94 (s, 3H, -CH3). 2.15 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.24, 163.38, 160.17, 158.42, 155.68, 148.48, 147.99, 139.14, 137.88, 135.55, 130.99, 131.53, 129.12, 128.11, 128.40, 127.31, 126.87, 123.92, 115.19, 112.10, 70.23, 66.05, 28.34, 30.21, 20.14, 13.99. Mass m/z: 576. Elemental Analysis: C30H28N6O6; Calculated: C, 56.20; H, 3.67; N, 14.57; Found: C, 56.14; H, 3.63; N, 14.54.
Yield: 82%, colour: dark brown colour powder, m.p. (°C): 195–198. IR (KBr, νmax, cm-1): 3261 (-N-H amidic), 3075 (=C-H aromatic), 2962 & 2900 (-C-H aliphatic), 1685 (-CONH amidic), 1641 & 1598 (-C=C aromatic), 1524 (-NO2 asymmetric), 1352 (NO2 symmetric), 1305 (-C-O-C asymmetric), 1175 (C-N), 1072 (-C-O-C symmetric), 675 & 710 (m-disubstituted aromatic), 1H NMR (400 MHz, DMSO) δppm: 12.04 (s, 1H, -NH), 8.40 (m, 1H, Phenyl), 8.32 (m, 1H, aromatic), 8.05 (m, 4H, aromatic), 7.88 (m, 1H, aromatic), 7.71 (d, J=6.0 Hz, 2H, aromatic), 7.00 (m, 2H, aromatic), 6.54 (d, J=5.2 Hz, 1H, aromatic), 4.70 (d, J=3.1, 2H, -CH2), 4.06 (s, 1H, Chiral -CH), 3.12 (s, 3H, -CH3) 2.94 (s, 3H, -CH3). 2.15 (s, 3H, -CH3). 13C NMR (101 MHz, DMSO) δppm: 165.41, 163.99, 162.34, 158.38, 155.89, 149.79, 148.78, 140.14, 139.88, 136.57, 129.12, 129.01, 128.80, 127.33, 126.36, 123.42, 115.19, 112.83, 70.13, 66.95, 28.37, 30.93, 13.85. Mass m/z: 599. Elemental Analysis: C29H25N7O8; Calculated: C, 58.10; H, 4.20; N, 16.35; Found: C, 58.06; H, 4.15; N, 16.32.
In vitro antidiabetic activity of synthesized compounds (4a-j) has been screened against alpha amylase (from Malt EC No. 232-588-1), using acarbose as a standard reference drug. The α-amylase inhibition assay was performed using the 3,5-dinitrosalicylic acid (DNSA) method. All the compounds were dissolved in 10% DMSO and were further dissolved in buffer at pH 6.9 to give concentrations ranging from 50–125 µg/mL. A volume of 200 µL of α-amylase solution (2 units/mL) was mixed with 200 µL of the dissolved compounds and was incubated for 10 minutes at 30°C. Thereafter, 200 µL of starch solution (1% in water (w/v)) was added to each tube and incubated for 3 minutes. The reaction was terminated by the addition of 200 µL DNSA reagent (12 g of sodium potassium tartrate tetra hydrate in 8.0 mL of 2 M NaOH and 20 mL of 96 mM of 3,5-dinitrosalicylic acid solution) and was boiled for 10 minutes in a water bath at 85-90°C. The mixture was cooled to ambient temperature and was diluted with 5 mL of distilled water, and the absorbance was measured at 540 nm using UV-Visible spectrometer. The blank with 100% enzyme activity was prepared by replacing the dissolved compounds with 200 µL of buffer. A blank reaction was similarly prepared using the dissolved compounds at each concentration in the absence of enzyme solution. A positive control was prepared using acarbose (150 µg/mL–50 µg/mL) and the reaction was performed similarly to the reaction with dissolved compounds as mentioned above. The α-amylase inhibitory activity was expressed as percentage inhibition and was calculated using the equation given below. The % of a-amylase inhibition graph was plotted against the IC50 value. Triplicates have been done for each sample.[
% of α amylase inhibition = 100 × Abs100% control – Abssample / Abs100% control
In the present study, we synthesized bioactive tetrahydropyrimidine analogues parade 1,3,4-oxadiazole pharmacophore. Synthesis of 1,3,4-oxadiazole based aldehyde (Fig.
Optimization reaction conditions and comparison for synthesized compound 4a
Entry | Solvent | Catalyst | Conventional Heatinga | Microwave assistedb | ||||
Temp (°C) | Time (hr) | Yield (%)c | Temp (°C) | Time (min) | Yield (%)c | |||
1 | MeOH | HCl | reflux | 21 | 12 | reflux | 20 | 22 |
2 | MeCN | HCl | reflux | 22 | trace | reflux | 22 | 16 |
3 | THF | HCl | reflux | 22 | trace | reflux | 20 | 11 |
4 | DMF | - | 100 | 20 | 24 | 100 | 19 | 39 |
5 | EtOH | HCl | reflux | 20 | 59 | reflux | 20 | 92 |
6 | MeOH | PPh3 | reflux | 21 | 19 | reflux | 20 | 32 |
7 | EtOH | PPh3 | reflux | 20 | 53 | reflux | 20 | 23 |
All synthesized compounds were evaluated for in vitro antidiabetic activity by alpha amylase inhibition strategy. Some of the compounds show good inhibition as compared with the standard drug acarbose. Compounds 4a (IC50=82.23), 4e (IC50=82.31), 4g (IC50=78.13), and 4i (IC50=83.41) show good inhibition and the rest of all compounds shows good to moderate inhibition. All details are presented in Table
Entry | Compound | Concentration (μg/mL) | % Inhibitiona | IC50 |
1 | 4a | 50 | 36.04±1.29 | 82.23 |
75 | 45.76±1.41 | |||
100 | 60.39±2.45 | |||
125 | 78.91±3.41 | |||
2 | 4b | 50 | 35.84±3.07 | 85.52 |
75 | 43.73±2.52 | |||
100 | 58.61±4.32 | |||
125 | 76.35±2.19 | |||
3 | 4c | 50 | 32.40±2.63 | 91.62 |
75 | 41.62±0.13 | |||
100 | 54.25±2.81 | |||
125 | 70.27±2.60 | |||
4 | 4d | 50 | 35.62±0.72 | 84.53 |
75 | 44.04±1.08 | |||
100 | 59.57±1.32 | |||
125 | 76.64±2.73 | |||
5 | 4e | 50 | 34.35±1.34 | 82.31 |
75 | 46.20±1.75 | |||
100 | 59.14±2.42 | |||
125 | 78.48±1.26 | |||
6 | 4f | 50 | 33.71±1.84 | 84.72 |
75 | 44.46±0.52 | |||
100 | 58.63±1.75 | |||
125 | 75.93±2.05 | |||
7 | 4g | 50 | 36.88±1.34 | 78.13 |
75 | 48.53±0.34 | |||
100 | 59.88±1.13 | |||
125 | 78.10±1.46 | |||
8 | 4h | 50 | 31.31±1.23 | 85.01 |
75 | 45.74±1.04 | |||
100 | 56.30±0.82 | |||
125 | 74.42±1.75 | |||
9 | 4i | 50 | 31.00±1.19 | 83.41 |
75 | 46.75±1.82 | |||
100 | 56.23±2.07 | |||
125 | 72.40±1.36 | |||
10 | 4j | 50 | 35.76±1.56 | 85.31 |
75 | 44.62±0.71 | |||
100 | 57.73±0.93 | |||
125 | 77.81±1.87 | |||
11 | Acarbose | 50 | 39.50±0.29 | 69.71 |
75 | 52.76±0.60 | |||
100 | 68.36±0.16 | |||
125 | 84.51±0.84 |
In this study, a series of 1,3,4-oxadiazole bearing tetrahydropyrimidine derivatives was synthesized by microwave irradiation method. All synthesized compounds were evaluated for in vitro antidiabetic screening. Derivatives 4a (IC50=82.23), 4e (IC50=82.31), 4g (IC50=78.13), and 4i (IC50=83.41) show excellent inhibition and the rest of the compounds show medium to moderate inhibition. All data are compared with the standard drug acarbose. In summary, new tetrahydropyrimidine derivatives may be used for their therapeutic potential and can serve as new therapies for diseases.
The authors have no support to report.
Authors are thankful to the School of Science, Department of Chemistry, RK University, Rajkot for providing all the facilities for completion of this work, and the National Facility for Drug Discovery (NFDD), Rajkot for providing spectral data.
Funding
The authors have no funding to report.
Competing Interests
The authors have declared that no competing interests exist.